Loading…
for educational and safety purposes
Tandospirone and Deramciclane both come up in the same conversations; they overlap on anxiety relief. Tandospirone: Tandospirone is a case of a drug that succeeded, just never where most of the archive's audience would notice; the azapirone was approved and marketed in Japan in 1996 as Sediel for generalized anxiety disorder, and later in China in 2004, where it remains in clinical use today for anxiety and, off-label, mood and psychotic-adjunct indications. Deramciclane: Deramciclane came out of EGIS Pharmaceuticals in Hungary as a non-benzodiazepine anxiolytic working through 5-HT2A/2C receptors instead of GABA-A, and Orion Pharma partnered on it to run one of the largest clinical programs in Orion's 20-year research history.
Tandospirone is a case of a drug that succeeded, just never where most of the archive's audience would notice; the azapirone was approved and marketed in Japan in 1996 as Sediel for generalized anxiety disorder, and later in China in 2004, where it remains in clinical use today for anxiety and, off-label, mood and psychotic-adjunct indications. It never sought FDA approval and stayed almost entirely off the radar in the US and Europe, overshadowed first by benzodiazepines and later by SSRIs. Its main pharmacological claim to fame is being one of the most selective 5-HT1A partial agonists among the azapirones, with comparatively little dopamine D2 or off-target receptor activity compared to relatives like buspirone.
Deramciclane came out of EGIS Pharmaceuticals in Hungary as a non-benzodiazepine anxiolytic working through 5-HT2A/2C receptors instead of GABA-A, and Orion Pharma partnered on it to run one of the largest clinical programs in Orion's 20-year research history. Early dose-finding data in generalized anxiety disorder actually looked encouraging; the 60 mg/day arm cleared the psychic-anxiety subscale of the HAM-A against placebo. That promise collapsed when the larger Phase III studies read out; Orion announced in 2003 that deramciclane simply lacked sufficient efficacy in GAD, closing out a program that had consumed years of investment on a hopeful mechanistic bet.
neither entry records receptor-level affinities yet; the ledgers above and each full entry carry what's known.